title: Novel targeted therapies for eosinophilic disorders.
abstract: Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders.
authors.affiliation: Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. mikewechsler@gmail.com
authors.forename: Michael E
authors.initials: ME
authors.lastname: Wechsler
authors.forename: Patricia C
authors.initials: PC
authors.lastname: Fulkerson
authors.forename: Bruce S
authors.initials: BS
authors.lastname: Bochner
authors.forename: Gail M
authors.initials: GM
authors.lastname: Gauvreau
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Gleich
authors.forename: Tim
authors.initials: T
authors.lastname: Henkel
authors.forename: Roland
authors.initials: R
authors.lastname: Kolbeck
authors.forename: Sameer K
authors.initials: SK
authors.lastname: Mathur
authors.forename: Hector
authors.initials: H
authors.lastname: Ortega
authors.forename: Jatin
authors.initials: J
authors.lastname: Patel
authors.forename: Calman
authors.initials: C
authors.lastname: Prussin
authors.forename: Paolo
authors.initials: P
authors.lastname: Renzi
authors.forename: Marc E
authors.initials: ME
authors.lastname: Rothenberg
authors.forename: Florence
authors.initials: F
authors.lastname: Roufosse
authors.forename: Dagmar
authors.initials: D
authors.lastname: Simon
authors.forename: Hans-Uwe
authors.initials: HU
authors.lastname: Simon
authors.forename: Andrew
authors.initials: A
authors.lastname: Wardlaw
authors.forename: Peter F
authors.initials: PF
authors.lastname: Weller
authors.forename: Amy D
authors.initials: AD
authors.lastname: Klion
mesh_terms: D000077944:Alefacept; D000074323:Alemtuzumab; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002465:Cell Movement / Q000187:drug effects; D002986:Clinical Trials as Topic; D004804:Eosinophils / Q000502:physiology*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D000069444:Omalizumab; D054735:Phosphorothioate Oligonucleotides / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; D054735:Phosphorothioate Oligonucleotides; D011993:Recombinant Fusion Proteins; C559988:TPI ASM8; D000069444:Omalizumab; C515492:reslizumab; D000074323:Alemtuzumab; C571386:benralizumab; C434107:mepolizumab; D000077944:Alefacept